Facilitated subcutaneous immunoglobulin (fSCIg) therapy – practical considerations

There is an increasing range of therapeutic options for primary antibody-deficient patients who require replacement immunoglobulin. These include intravenous immunoglobulin (IVIg), subcutaneous immunoglobulin (SCIg), rapid push SCIg and most recently recombinant human hyaluronidase-facilitated SCIg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Exp Immunol
Autors principals: Ponsford, M, Carne, E, Kingdon, C, Joyce, C, Price, C, Williams, C, El-Shanawany, T, Williams, P, Jolles, S
Format: Artigo
Idioma:Inglês
Publicat: John Wiley & Sons, Ltd 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4636892/
https://ncbi.nlm.nih.gov/pubmed/26288095
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.12694
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars